# Starling Oncology, Inc.: Form 8-K, filed Mar 25, 2025

- Company: [Starling Oncology, Inc.](/companies/stln.md) (CIK 1799191)
- Form: 8-K
- Filed: 2025-03-25
- Accepted by EDGAR: Mar 25, 2025, 06:05 ET
- Period: 2025-03-24
- Accession: 0001079973-25-000460
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000460/toi_8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1799191/000107997325000460/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 3.02: Unregistered sale of equity
- Item 3.03: Change to security holders’ rights
- Item 5.03: Amendment to articles or bylaws
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1799191/000107997325000460/toi_8k.htm

Filed Mar 25, 2025.
Source: SEC EDGAR, the filing index for accession 0001079973-25-000460. Last ingested by Listed: Nov 15, 2026, 04:34 ET. No prices; not investment advice.
